Finnish researchers find a compound that prevents the growth of prostate cancer cells
Researchers from VTT Technical Research Centre of Finland and the University of Turku have demonstrated that an antibiotic called “monensin” prevents the growth of prostate cancer cells. Monensin is used in the meat and dairy industry, for example.
Arsenic agent shuts down 2 hard-to-treat cancers in animal experiments
Researchers at the Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center, have found that an arsenic-based agent already FDA-approved for a type of leukemia may be helpful in another hard-to-treat cancer, Ewing's Sarcoma (ES). The research, based on animal studies, also suggests the drug might be beneficial in treating medulloblastoma, a highly malignant pediatric brain cancer.
High Red Blood Folate Levels Linked to Silenced Tumor-Suppressors
People with higher levels of folate in their red blood cells were more likely to have two cancer-preventing genes shut down by methylation -- a chemical off switch for genes, researchers report this week in the December issue of Cancer Prevention Research.
Y-90 Radioembolization Offers Promise for Late-Stage Liver Cancer
The latest weapon against inoperable liver cancer is so tiny that it takes millions of them per treatment, but according to interventional radiologists at the Indiana University School of Medicine, those microscopic spheres really pack a therapeutic punch.
Prostate cancer drug targeting Vit D receptors shows promise
Inecalcitol, a novel anti-cancer drug aimed at vitamin D receptors delivered "encouraging" results in the treatment of hormone refractory prostate cancer, reported a French abstract presented at the 22 nd EORTC-NCI-ACCR Symposium on Molecular Targets and Cancer Therapeutics (16 to 19 November, Berlin, Germany).